All‐cause death ( · preventing the progression of CKD
Metformin showed no clear difference in all‐cause death ( compared with active control (low certainty).
1 finding from 1 review
Word retrieval · adults with primary progressive aphasia (PPA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall language abilities · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Cognitive function · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Quality of life · adults with primary progressive aphasia (PPA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Clinical remission · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes clinical remission (14 days) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Clinical improvement (Rachmilewitz index) (14 days) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
Clinical relapse · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people in remission or with mildly activeulcerative colitis
1 finding from 1 review
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with probiotics (very low certainty).
1 finding from 1 review
Clinical relapse · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people in remission or with mildly activeulcerative colitis
1 finding from 1 review
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
1 finding from 1 review